Eversept Partners LP Invests $12.19 Million in Pharvaris N.V. $PHVS

Eversept Partners LP bought a new stake in shares of Pharvaris N.V. (NASDAQ:PHVS) in the 4th quarter, Holdings Channel.com reports. The firm bought 439,177 shares of the company’s stock, valued at approximately $12,187,000.

Other large investors have also bought and sold shares of the company. GF Fund Management CO. LTD. bought a new position in Pharvaris during the fourth quarter valued at about $35,000. JPMorgan Chase & Co. boosted its stake in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Pharvaris during the third quarter valued at about $75,000. Barclays PLC bought a new position in Pharvaris during the fourth quarter valued at about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Pharvaris during the fourth quarter valued at about $86,000.

Analyst Upgrades and Downgrades

PHVS has been the subject of several research reports. Citizens Jmp decreased their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Royal Bank Of Canada decreased their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. UBS Group set a $74.00 target price on Pharvaris in a research note on Wednesday, May 13th. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Finally, Wolfe Research initiated coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price for the company. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $49.18.

Pharvaris Stock Up 6.2%

Shares of NASDAQ PHVS opened at $33.41 on Thursday. Pharvaris N.V. has a 12 month low of $16.00 and a 12 month high of $33.50. The company has a market cap of $2.19 billion, a price-to-earnings ratio of -10.51 and a beta of -2.35. The business has a fifty day simple moving average of $29.81 and a 200-day simple moving average of $27.67.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. As a group, sell-side analysts expect that Pharvaris N.V. will post -3.22 EPS for the current fiscal year.

Insider Buying and Selling at Pharvaris

In related news, Director Elisabeth Bjork sold 10,000 shares of the stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $29.32, for a total value of $293,200.00. Following the completion of the sale, the director directly owned 15,167 shares of the company’s stock, valued at approximately $444,696.44. This represents a 39.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Berndt Modig sold 2,291 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $31.07, for a total value of $71,181.37. Following the completion of the sale, the chief executive officer directly owned 135,209 shares of the company’s stock, valued at approximately $4,200,943.63. This represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 214,909 shares of company stock valued at $6,421,745 over the last 90 days. 11.84% of the stock is owned by insiders.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.